Jennifer Marion
Adult Health · Elkin, NCNPI 1801051032
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,871 of the $4,720 with a category attached, or 82.0%. 27 manufacturers reported payments, led by Medtronic at 31.9% of the total. Among adult health clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $26.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$819
- Lilly USA, LLC$330
- AstraZeneca$281
- Dexcom, Inc.$234
- Tandem Diabetes Care, Inc.$165
- plus $1K from 21 others
What the payments were for
- Travel & lodging$84918%
- Food & beverage$3,87182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 29 | $1,504 |
| Novo Nordisk | 48 | $819 |
| Lilly USA, LLC | 19 | $330 |
| AstraZeneca(2 entities) | 14 | $281 |
| Dexcom, Inc. | 5 | $234 |
| Tandem Diabetes Care, Inc. | 8 | $165 |
| Cequr Corporation | 2 | $163 |
| Amgen(2 entities) | 7 | $130 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $124 |
| Xeris Pharmaceuticals, Inc. | 6 | $112 |
| Madrigal Pharmaceuticals | 3 | $101 |
| Sanofi-aventis U.S. LLC | 4 | $97 |
| Phathom Pharmaceuticals, Inc. | 1 | $85 |
| Mannkind Corporation | 4 | $82 |
| AbbVie | 3 | $70 |
| Corcept Therapeutics | 4 | $69 |
| Bayer | 4 | $67 |
| BETA Bionics, Inc. | 2 | $48 |
| Boehringer Ingelheim | 3 | $42 |
| Insulet Corporation | 2 | $41 |
| Abbott | 2 | $35 |
| Novartis | 1 | $27 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $22 |
| Shield Therapeutics Inc | 1 | $18 |
| Tolmar, Inc. | 1 | $16 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,720 in reported general payments places this provider in the 90th percentile of 614 adult health providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 239 | $258,141 |
| MounjaroTirzepatide | 129 | $152,844 |
| JardianceEmpagliflozin | 124 | $109,586 |
| Tresiba Flextouch U-200Insulin Degludec | 85 | $101,951 |
| FarxigaDapagliflozin Propanediol | 110 | $84,468 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $75,980 |
| TrulicityDulaglutide | 44 | $57,933 |
| Humalog Kwikpen U-200Insulin Lispro | 52 | $51,554 |
| Tresiba Flextouch U-100Insulin Degludec | 78 | $50,485 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 20 | $35,930 |
| RybelsusSemaglutide | 16 | $25,278 |
| EliquisApixaban | 22 | $21,271 |
| JanuviaSitagliptin Phosphate | 27 | $19,153 |
| TradjentaLinagliptin | 32 | $16,783 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $15,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $819 | $283,419255 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $330 | $213,999192 claims |
| Boehringer IngelheimJardiance, Tradjenta | $42 | $126,369156 claims |
| AstraZenecaFarxiga | $281 | $84,468110 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $14 | $28,37341 claims |
| BayerKerendia | $67 | $11,74218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 adult health providers in North Carolina.
Other adult health in Elkin
- Robert DodgeRaleigh$311K
- Kimberly CampDurham$147K
- Henry VanpalaRaleigh$110K
- Jolene SpencerWashington$83K
- Felicia RichardsonGreenville$64K
- Anna BooneReidsville$51K
- Chaely MedleyChapel Hill$47K
- Ann ShumDurham$35K
- Amy HopkinsGreenville$31K
- Stephanie YatesDurham$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.